NAD | Jotup

NIO Automaker Strategy Research Report - In 2022 NIO Will Deliver 3 New Models

Retrieved on:

Monday, May 23, 2022

ES6, Orin, Coffee, APP, City, ES7, ELK, Memory, Model Y, NIO, Hearing, Automatic parking, ADAS, NVIDIA, ADMS, DRIVE, Radar, Marketing, BMW, Research, Watchtower, EAS, Hobby, Safety, IVI, Sale, PSAP, EC6, Lidar, NAD, Record, OTA, Car dealership, Online shopping, Mobile phone, Satellite navigation device, Broadcasting

DUBLIN, May 23, 2022 /PRNewswire/ --The "Emerging Automakers Strategy Research Report, 2022 - NIO" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, May 23, 2022 /PRNewswire/ --The "Emerging Automakers Strategy Research Report, 2022 - NIO" report has been added to ResearchAndMarkets.com's offering.
This report contains research on emerging carmaking strategies: no new cars in 2021, 3 new cars in 2022, can NIO make its renaissance?
In 2022, NIO will deliver three new models one after another, and its sluggish sales status is expected to fade out.
NIO Value: It is an accumulated value that records each user's activities in NIO community and his/her contribution to the community.

Wonderfeel® to Launch Youngr™, Targeting the Root Causes of Aging

Retrieved on:

Thursday, May 19, 2022

SAN FRANCISCO, May 19, 2022 /PRNewswire/ -- Wonderfeel® [www.getwonderfeel.com], a frontrunner in wellness biosciences, announces U.S. patent application, and largest human clinical trial for their launch of Youngr™, a revolutionary synthesis combining NMN, the most direct NAD precursor (nicotinamide adenine dinucleotide), with emergent antioxidants creating a predominant supplement to maximize healthspan. The result is a first of its kind patented solution to increase the production of NAD, which begins declining once adults are in their 30s, and is responsible for biological aging at the cellular level. The benefits of reversing this decline include improved cognition, energy levels, skin elasticity, overall organ health, and more (full benefits found here). Youngr™ is now available to order at www.getwonderfeel.com.

Key Points:

"From a historical perspective, we are at an inflection point in biosciences where we can advance people's well-being to unprecedented levels.
To achieve such levels, a two pronged approach is crucial," says Baran Dilaver, Co-Founder of Wonderfeel.
With the launch of Youngr, Wonderfeel has advanced that science for those who will benefit most adults ages 35+.
Founded in Silicon Valley in 2018, Wonderfeel is a team of pioneering doctors, creators, entrepreneurs, and scientists, who set out to accelerate wellness technologies through bioscience.

ReGenMed and the University of Helsinki Collaborate Their Expertise on NAD+ Human Clinical Study

Retrieved on:

Wednesday, May 18, 2022

NAD+, a coenzyme referred to as "The Fountain of Youth Molecule", in a first-of-a-kind clinical study with top European university.

Key Points:

Bangkok, Thailand--(Newsfile Corp. - May 18, 2022) - ReGenMed is pleased to announce results of their exciting collaboration and clinical study with the University of Helsinki focused on their recent FDA-approved, proprietary NAD+ product called InfiNADi NAD+.
The study measured the rate of absorption of infused NAD+ with six unique metabolites produced by the human body.
Company logo of Regenerative Medicine Co., Ltd. (ReGenMed), an up-and-coming biotech company that's disrupting the industry with their innovative advance anti-aging biomedicines.
The University of Helsinki is one of the most advanced and respected institutes in Europe.

2022 Emerging Automakers Strategy Research Report - NIO - ResearchAndMarkets.com

Retrieved on:

Wednesday, May 18, 2022

General Automotive, Automotive Manufacturing, Manufacturing, Automotive, ES6, Orin, APP, City, ES7, ELK, Memory, Model Y, NIO, Hearing, Automatic parking, ADAS, NVIDIA, ADMS, DRIVE, Radar, Marketing, BMW, Research, Watchtower, EAS, Safety, IVI, PSAP, EC6, Lidar, NAD, OTA, Car dealership, Mobile phone, Satellite navigation device, Broadcasting

The "Emerging Automakers Strategy Research Report, 2022 - NIO" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Emerging Automakers Strategy Research Report, 2022 - NIO" report has been added to ResearchAndMarkets.com's offering.
This report contains research on emerging carmaking strategies: no new cars in 2021, 3 new cars in 2022, can NIO make its renaissance?
However, its ranking among emerging automakers by sales volume dropped from the first in 2020 to the third.
In 2022, NIO will deliver three new models one after another, and its sluggish sales status is expected to fade out.

ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®

Retrieved on:

Tuesday, May 17, 2022

ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients , a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERPTM) with a 2022 European NutraIngredients Award in the Nutrition Research Project category for developing the science behind ChromaDexs proprietary and patented Niagen nicotinamide riboside (NR) ingredient.

Key Points:

ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients , a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERPTM) with a 2022 European NutraIngredients Award in the Nutrition Research Project category for developing the science behind ChromaDexs proprietary and patented Niagen nicotinamide riboside (NR) ingredient.
View the full release here: https://www.businesswire.com/news/home/20220517005235/en/
ChromaDex Wins 2022 NutraIngredients Award for Developing the Science Behind Niagen (Graphic: Business Wire)
Honoring the best and brightest in ingredients, products, companies, people, and initiatives in the nutrition and dietary supplement industry, the NutraIngredients Awards spotlight innovation, long-term market success, and cutting-edge research.
CERP differentiates ChromaDex from other companies because the science is expansive and is primarily investigator driven, and third-party funded.
For additional information on ChromaDexs 2022 NutraIngredients Award, please click www.nutraingreients-awards.com and for more on the science supporting Niagen visit www.chromadex.com .

ChromaDex Corporation Reports First Quarter 2022 Financial Results

Retrieved on:

Thursday, May 12, 2022

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022.

Key Points:

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022.
We delivered solid financial results in the first quarter, while strengthening our patent portfolio, and announcing dramatic new scientific research on Niagen(R), said CEO, Rob Fried.
Following the quarter, we launched Tru Niagen(R) Immune and ramped up our new TV campaign to encouraging early results.
Results of operations for the three months ended March 31, 2022 compared to the prior year quarter
For the three months ended March 31, 2022 (Q1 2022), ChromaDex reported net sales of $17.3 million, up $2.6 million or 18% compared to the first quarter of 2021 (Q1 2021).

National Advertising Review Board Recommends Merck Discontinue "Best in Show" Commercial for Bravecto Flea and Tick Preventative for Dogs

Retrieved on:

Thursday, May 5, 2022

Privacy, Schering-Plough, Best in Show, Council, Merck, Uniloc USA, Inc. v. Microsoft Corp., CARU, Public sector, Fluralaner, Industry, Compliance, Advertising, Better Business Bureau, Tick, View, Afoxolaner, NAD, Multimedia, Pharmaceutical industry

The advertising at issue had been challenged before the National Advertising Division (NAD) by Boehringer Ingelheim Animal Health USA Inc., maker of NexGard.

Key Points:

The advertising at issue had been challenged before the National Advertising Division (NAD) by Boehringer Ingelheim Animal Health USA Inc., maker of NexGard.
7029 ), Merck appealed NAD's recommendation that it discontinue its 30-second "Best in Show" television commercial.
About BBB National Programs:BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard.
About the National Advertising Review Board (NARB):The National Advertising Review Board(NARB)is the appellate body for BBB National Programs' advertising self-regulatory programs.

National Advertising Division Finds Certain Apartments.com Website Claims Supported; Advertiser CoStar Group Appeals Other Findings

Retrieved on:

Wednesday, May 4, 2022

During the proceeding, the advertiser agreed to permanently discontinue the claim "We deliver the highest quality, ready-to-move renters," and to permanently modify several claims.

Key Points:

During the proceeding, the advertiser agreed to permanently discontinue the claim "We deliver the highest quality, ready-to-move renters," and to permanently modify several claims.
Such appeals of NAD decisions are made to the BBB National Programs' National Advertising Review Board (NARB), the appellate-level truth-in-advertising body of BBB National Programs.
About BBB National Programs:BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard.
About the National Advertising Division:TheNational Advertising Division (NAD) of BBB National Programsprovidesindependent self-regulationand dispute resolution services,guidingthe truthfulness of advertising across the U.S. NADreviews national advertising in all media and its decisions set consistent standards foradvertisingtruth and accuracy, delivering meaningful protection toconsumersand leveling the playing field for business.

Ketamine Wellness Centers (KWC) Introduces NAD+ Infusion Therapy

Retrieved on:

Wednesday, May 4, 2022

Reality Sandwiches, Brain, Physician, Depression, NAD, Patient, Immunity, CSE, FRA, Delić, Ketamine, Industry, Anxiety, DNA, Signal, Veteran, Method, PTSD, Education, View, Health Canada, Chronic pain, IV, Mental health, OCD, CEO, KWC, Research, DELC, Cell, Multimedia, Pharmaceutical industry, Online shopping

"The introduction of NAD+ infusion therapy to our clinics is a strong complement to ketamine therapy and has benefits for their mental and physical well-being.

Key Points:

"The introduction of NAD+ infusion therapy to our clinics is a strong complement to ketamine therapy and has benefits for their mental and physical well-being.
For more information about Ketamine Wellness Centers' locations, services and hours of operation, please visit https://www.ketaminewellnesscenters.com/locations /.
Ketamine Wellness Centers (KWC) is the largest ketamine therapy provider in the United States with 13 clinic locations serving communities across nine states.
Since 2011 KWC has been a trusted leader in bringing IV ketamine therapy into mainstream health care.

Bragg Survey Reveals Consumer Perception About Health Claims of Apple Cider Vinegar Gummy Supplements

Retrieved on:

Tuesday, May 3, 2022

SANTA BARBARA, Calif., May 3, 2022 /PRNewswire/ -- Bragg Live Food Products, Inc., ("Bragg"), one of the oldest and most trusted health and wellness brands and the leading U.S. brand of apple cider vinegar (ACV), today announced findings from a national consumer survey conducted by market research firm Ipsos regarding the perception of health benefits of ACV in liquid and supplement forms.

Key Points:

Among current users of ACV, 58% believe that apple cider vinegar gummies provide the same health benefits as liquid apple cider vinegar.
"First and foremost, we want consumers to be aware of unsubstantiated health claims of ACV supplements delivered in gummy supplement format, and we advocate for more transparency in product labeling," says Linda Boardman, Bragg's CEO.
Apple cider vinegar has been used for years by consumers as part of their health and wellness routines.
Beyond their famous Apple Cider Vinegar, Bragg's product family consists of a wide range of offerings including apple cider vinegar shots, olive oil, seasonings, salad dressings, beverages, supplements, and more.